Scottsdale, Ariz. – September 19, 2026 -- CND Life Sciences, Inc. has opened a new Innovation Laboratory in Scottsdale, Arizona, expanding its research and product-development capacity for neurodegenerative disease diagnostics. The facility was inaugurated with a ribbon-cutting ceremony attended by employees, community members, and key stakeholders, and operations are set to begin next week.
New facility separates R&D from clinical testing operations
The Innovation Laboratory operates independently from CND's existing CLIA-certified, CAP-accredited, and CLEP-permitted clinical laboratory, which processes the company's Syn-One Test. The new space is dedicated to assay development, biomarker research, technology evaluation, and translational research programs, allowing the company to pursue early-stage science without disrupting clinical throughput.
Executives frame the lab as a growth investment tied to Arizona's biotech sector
Todd Levine, MD, Chief Medical Officer and Co-Founder of CND, said the opening marks an important milestone, reflecting the company's investment in its people, scientific capabilities, and long-term vision to better serve clinicians, patients, researchers, and partners. Located near CND's headquarters and central laboratory operations, the facility is designed to enable closer collaboration among scientific, product development, operational, and leadership teams. The company also positioned the investment as a contribution to Arizona's growing biotechnology and medical technology community.
CSO says the lab will accelerate work on synucleinopathy therapeutics
Christopher Gibbons, MD, Chief Scientific Officer and Co-Founder, said the Innovation Laboratory strengthens CND's ability to explore new scientific opportunities, advance precision neurodiagnostic medicine, and support development of novel therapeutic treatments for degenerative diseases.
Syn-One Test has been used on more than 70,000 patients by over 3,500 clinicians
CND's flagship product, the Syn-One Test, is a laboratory developed test used to aid clinicians in diagnostic evaluation of patients with suspected synucleinopathies, including Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. The test detects phosphorylated alpha-synuclein in cutaneous nerves and measures other signs of peripheral nerve degeneration. A prospective, multicenter, NIH-sponsored study published in JAMA in 2024 found phosphorylated alpha-synuclein in 95.5% of participants clinically diagnosed with a synucleinopathy. CND also collaborates with biopharmaceutical companies on clinical trials for investigational therapies and is conducting studies on early disease detection and synuclein quantification.